Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…
Like AMG 510, MRTX849 yields partial responses in some lung and colorectal tumours, but investors could have expected better.
Today’s deal with Blueprint gives Ipsen two shots at Fop, but makes its takeout of Clementia look even more expensive.
Healx's "hypothesis-free" approach proves a big draw to investors despite the early-stage nature of the group's projects.
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
Amgen’s AMG 510 disappoints Kras bulls, showing just two new partial responses, in colorectal and appendiceal tumours.
As J&J tears up a licensing deal with Alligator, CD40 agonism might join the likes of Ox40 and IDO as an immuno-oncology approach that has failed to deliver.